The Discounted Cash Flow (DCF) valuation of Lineage Cell Therapeutics Inc (LCTX) is (2.04) USD. With the latest stock price at 0.46 USD, the upside of Lineage Cell Therapeutics Inc based on DCF is -540.5%.
Based on the latest price of 0.46 USD and our DCF valuation, Lineage Cell Therapeutics Inc (LCTX) is a sell. selling LCTX stocks now will result in a potential gain of 540.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 7.2% - 9.3% | 8.2% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (3.96) - (1.37) | (2.04) |
| Upside | -954.7% - -395.9% | -540.5% |